search
The pharmaceutical industry develops therapies using a variety of molecular approaches. Two of the most prominent categories are small molecule drugs and biologics, each offering unique advantages depending on the disease target and treatment strategy.
Mar 27, 2026
Cryogenic chemistry plays a critical role in the synthesis of many active pharmaceutical ingredients (APIs). By operating at very low temperatures (typically between -20°C and -90°C), chemists can reduce impurities, improve selectivity, and enhance safety for highly reactive transformations. These advantages make cryogenic reactions a powerful enabler in drug development.
Mar 27, 2026
Highly potent active pharmaceutical ingredients (HPAPIs) continue to represent one of the fastest-growing segments of the pharmaceutical industry, driven largely by an increasing focus on targeted therapeutics like antibody-drug conjugates (ADCs).
Mar 25, 2026
Oxidation reactions play a central role in chemical synthesis, enabling medicinal chemists to functionalize molecules while controlling reactivity and selectivity. At manufacturing scale, however, oxidation chemistry presents safety and operational challenges that often push teams toward alternative transformations.
Mar 24, 2026
Early-stage drug development is fast-moving and rarely predictable. As evidence evolves and priorities shift, sponsors need partners that can adapt quickly without compromising quality or timelines. In a recent case study, we illustrated how integrated drug development and manufacturing operations can provide the flexibility required to keep early programs moving forward, even when unexpected challenges arise.
Mar 24, 2026
